Sogroya's EU ISS First-Mover Label: Regulatory Win, Reimbursement Battle Ahead

CHMP Recommends Novo Nordisk's Sogroya for Pediatric Idiopathic Short Stature

Novo Nordisk announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature (ISS) and persistent growth disturbance. This condition affects up to 3% of children worldwide and currently has limited treatment options. If approved by the European Commission, Sogroya would be the first and only growth hormone treatment specifically for ISS in the EU. This recommendation builds on earlier positive opinions for Sogroya in children with short stature due to Small for Gestational Age (SGA) and Noonan Syndrome (NS) in May 2026. A final marketing authorisation decision from the European Commission, covering all three indications, is anticipated later this year.

• The Committee for Medicinal Products for Human Use (CHMP) has recommended Novo Nordisk's once-weekly Sogroya (somapacitan) for children in Europe with idiopathic short stature (ISS) and persistent growth disturbance. This is a significant step towards addressing an unmet medical need, as ISS affects up to 3% of children worldwide and currently lacks approved growth hormone treatments in the EU. The recommendation offers hope for families who often feel unseen and face limited options for managing this condition.
• The positive CHMP opinion is supported by data from the REAL8 Phase 3 clinical trial, which demonstrated that once-weekly Sogroya was non-inferior to once-daily growth hormone treatment for mean annualised height velocity at Week 52 in children with growth disorders, including ISS. Sogroya is a long-acting human growth hormone analogue administered as a single subcutaneous injection once a week, utilizing albumin-binding technology to prolong its presence in the body.
• This recommendation for ISS follows previous positive CHMP opinions for Sogroya in May 2026 for the treatment of short stature in children born Small for Gestational Age (SGA) and with Noonan Syndrome (NS). Sogroya is already authorised in the EU for growth hormone deficiency in adults (March 2021) and in children aged 3 years and older (July 2023). The European Commission is expected to make a final decision on marketing authorisation for all three indications (ISS, SGA, NS) later this year.

Addressing the Unmet Needs in Idiopathic Short Stature

Treatment of idiopathic short stature (ISS) presents a complex clinical landscape where the pace of pubertal bone maturation fundamentally constrains the window available for therapeutic intervention. The relentless tempo of bone age acceleration driven by sex steroids — estrogen in particular — limits the time available for linear growth, reducing the overall impact of growth hormone (GH) therapy. Current and emerging adjunctive strategies each carry meaningful trade-offs that complicate clinical decision-making.

• GH dose escalation yields diminishing returns with safety concerns. High-dose GH use has shown dose-dependent increases in linear growth in ISS, but can raise insulin-like growth factor I concentrations supraphysiologically and increase treatment costs, creating a ceiling on the practical utility of dose intensification.

• GnRH analog (GnRHa) use introduces a critical developmental compromise. When used in combination with GH to suppress puberty and extend the growth window, GnRHas can meaningfully increase height potential in males and females, but render adolescents temporarily hypogonadal at a critical period in development — a trade-off with significant implications for bone health, psychosocial maturation, and long-term endocrine function.

• Aromatase inhibitors remain off-label with incomplete efficacy and safety data. Anastrozole, letrozole, and exemestane are under investigation in adolescent subjects with severe growth retardation, but their use in ISS represents off-label application, and definitive data on efficacy are not available for each of the conditions in which they are being studied. Safety issues regarding bone health also require further study.

• Daily injection burden undermines adherence and quality of life. Daily subcutaneous injections impose a significant burden on children and families, negatively affecting adherence to GH therapy. Identifying factors that support or hinder adherence — and the development of long-acting formulations — are recognized as important priorities for improving treatment-related quality of life and outcomes.

Sogroya's Potential to Reshape the ISS Treatment Landscape

The treatment landscape for idiopathic short stature (ISS) has seen meaningful advancement through the clinical evaluation of long-acting, once-weekly pegylated recombinant human growth hormone (PEG-rhGH) formulations as alternatives to the established standard of daily rhGH. A multicenter, randomized phase II study enrolling 360 children with ISS demonstrated that 52 weeks of weekly PEG-rhGH at either 0.1 or 0.2 mg/kg/week produced statistically significant, dose-dependent improvements in height SDS (ΔHT-SDS of 0.56 ± 0.26 and 0.98 ± 0.35 in the low- and high-dose groups, respectively, versus 0.20 ± 0.26 in controls; P < 0.0001), as well as in height velocity, IGF-1 SDS, and IGF-1/IGFBP-3 molar ratio. A subsequent systematic review and meta-analysis of eight studies comprising 2,549 children confirmed that once-weekly PEG-rhGH achieves comparable short-term growth outcomes to daily rhGH at 6 and 12 months, with modest but statistically significant superiority emerging by 24 months in height SDS (MD = 0.10, 95% CI 0.01–0.19) and height velocity (MD = 0.74 cm/year, 95% CI 0.42–1.05). The higher PEG-rhGH dose of 0.2 mg/kg/week produced substantially greater gains in height SDS and IGF-1 SDS than 0.1 mg/kg/week, with a time-dependent increase in the magnitude of effect.

Alongside the long-acting GH data, the phase 3 randomized controlled trial of daily somatropin (0.05 mg/kg/day) in 481 prepubertal Chinese children with ISS reinforced the efficacy of conventional daily therapy, reporting a ΔHT-SDS of 1.04 ± 0.31 versus 0.20 ± 0.33 in controls at 52 weeks (P < 0.001), with corresponding improvements in height velocity (5.17 ± 3.70 cm/year vs. 0.75 ± 4.34 cm/year; P < 0.001) and IGF-1 SDS (2.31 ± 1.20 vs. 0.22 ± 0.98; P < 0.001). An earlier meta-analysis of 11 studies (1,232 children) offered a more cautious comparative perspective, finding that long-acting GH was associated with significantly lower height SDS for chronological age (MD, −0.10; 95% CI, −0.13 to −0.08; P < 0.001) and lower IGFBP-3 relative to daily GH, with no significant differences in height velocity, height SDS for bone age, IGF-1 SDS, or adverse event incidence — underscoring that the comparative evidence base continues to mature.

The evolving landscape has also incorporated combination strategies aimed at optimizing adult height outcomes. In girls with short stature and advanced bone age, a retrospective study of 29 patients treated with rhGH, GnRH analogue (GnRHa), and letrozole reported a predicted adult height gain (ΔPAH) of 5.85 cm, compared with 1.82 cm in the rhGH/GnRHa control group (P < 0.001), with no significant side effects reported. Across the broader literature, GnRHa co-treatment and aromatase inhibitor use have been explored off-label to delay skeletal maturation and extend the growth window, though conclusions on attained adult height remain limited by the availability of long-term follow-up data. Safety analyses across the PEG-rhGH studies consistently showed no increase in adverse or serious adverse events relative to daily rhGH, with treatment-emergent adverse events generally mild and transient — a profile that, combined with the adherence advantage of weekly dosing, positions long-acting formulations as an increasingly viable option within the ISS treatment paradigm.

REAL8 Trial Data Supporting Sogroya's Efficacy in ISS

Recent literature highlights several studies examining interventions for idiopathic short stature (ISS) and related short stature conditions, spanning pharmacological and novel approaches. The findings below reflect key safety and efficacy data from these investigations.

The knowledge base does not have sufficient information on this aspect.

Sogroya's EU Expansion: A New Horizon for Idiopathic Short Stature

The recent positive opinion from the European Medicines Agency's CHMP for Novo Nordisk's once-weekly Sogroya (somapacitan) in children with idiopathic short stature (ISS) marks a pivotal moment for pediatric endocrinology. If approved, Sogroya would become the first and only long-acting growth hormone (LAGH) specifically indicated for ISS in the EU, a condition affecting a substantial number of children with limited treatment options. This recommendation builds on earlier positive opinions for Sogroya in Small for Gestational Age (SGA) and Noonan Syndrome, solidifying its position as a versatile LAGH therapy.

The strategic importance of this development lies in addressing the significant treatment burden associated with daily growth hormone injections. Research consistently highlights that once-weekly LAGH formulations can improve patient adherence and preference, which are critical factors for achieving optimal long-term growth outcomes. Studies have shown that LAGH products, including somapacitan, offer comparable or even superior efficacy to daily growth hormone in conditions like GHD and SGA, with similar safety profiles. Importantly, preliminary studies suggest that LAGH does not suppress endogenous growth hormone secretion in ISS patients, which is a key consideration for this population.

However, stakeholders should consider certain nuances. While LAGH is effective in ISS, some evidence indicates that the magnitude of efficacy, such as improvements in height standard deviation score, might be less pronounced in ISS patients compared to those with GHD. This suggests that while beneficial, the clinical response in ISS may differ. Furthermore, while long-term data for somapacitan in SGA are robust, comprehensive long-term efficacy and safety data specifically for ISS patients treated with LAGH are still evolving and warrant continued investigation. Despite the clear advantages in reducing treatment burden, it is also worth noting that real-world studies on daily GH adherence have sometimes shown only minor, non-statistically significant improvements in height velocity even with good adherence, implying that adherence is one of several factors influencing overall growth outcomes. Novo Nordisk's move positions Sogroya to redefine the standard of care for a broader spectrum of short stature conditions, emphasizing patient convenience and adherence as key drivers for therapeutic success.